EWA
NTLA icon

EverSource Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

EverSource Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.82K Sell
462
-232
-33% -$3.25K ﹤0.01% 3054
2026
Q1 		$8.9K Buy
694
+390
+128% +$4.97K ﹤0.01% 2976
2025
Q4 		$2.73K Sell
304
-231
-43% -$3.18K ﹤0.01% 3382
2025
Q3 		$9.24K Buy
535
+73
+16% +$899 ﹤0.01% 2866
2025
Q2 		$4.33K Buy
462
+57
+14% +$468 ﹤0.01% 3220
2025
Q1 		$2.88K Buy
405
+135
+50% +$1.36K ﹤0.01% 2747
2024
Q4 		$3.15K Sell
270
-1,477
-85% -$23.1K ﹤0.01% 2539
2024
Q3 		$35.9K Sell
1,747
-6
-0.3% -$138 ﹤0.01% 1208
2024
Q2 		$45.9K Buy
1,753
+1,550
+764% +$36.9K ﹤0.01% 1126
2024
Q1 		$4.34K Buy
203
+1
+0.5% +$28 ﹤0.01% 2108
2023
Q4 		$6.16K Buy
202
+40
+25% +$1.15K ﹤0.01% 1772
2023
Q3 		$5.12K Buy
162
+96
+145% +$3.72K ﹤0.01% 1704
2023
Q2 		$2.69K Buy
+66
New +$2.68K ﹤0.01% 1948
2022
Q2 		– Sell
-44
Closed -$3K – 1834
2022
Q1 		$3K Hold
44
– – ﹤0.01% 1434
2021
Q4 		$5K Buy
+44
New +$5.51K ﹤0.01% 1269

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

EverSource Wealth Advisors's NTLA Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Intellia Therapeutics (NTLA) stake by 33% in Q2 2026, selling an estimated $3.25K and leaving 462 shares worth $7.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3054.

EverSource Wealth Advisors first reported a position in NTLA in Q4 2021 and has held it in 15 quarters since. The position peaked at $45.9K in Q2 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • EverSource Wealth Advisors held 462 shares of Intellia Therapeutics worth $7.82K as of Q2 2026.
  • EverSource Wealth Advisors sold 232 Intellia Therapeutics shares in Q2 2026, an estimated $3.25K.
  • Intellia Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3054 holding.
  • EverSource Wealth Advisors first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • EverSource Wealth Advisors's Intellia Therapeutics position peaked at $45.9K in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.